Trial Profile

A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Aug 2025 Planned End Date changed from 30 Oct 2026 to 31 Dec 2026.
03 Aug 2025 Planned primary completion date changed from 30 Jun 2025 to 31 Dec 2026.
08 Apr 2025 According to an Ocugen media release, Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will participate in a panel addressing the journey of commercializing Advanced Therapy Medicinal Products (ATMPs) including OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy and OCU410ST for Stargardt disease, at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com